Navigation Links
Defensive measures: Toward a vaccine for Ebola
Date:12/5/2011

ing antibodies to attack the virus directlya process known as passive immunization, combined with a vaccine to stimulate the protective immune response (active immunization). This approach is commonly used in the case of other viral infections, particularly rabies. "Our two papers offer a nice back to back picture," Arntzen says. "We can manufacture both of these post-Ebola exposure reagents for a defensive stockpile, using tobacco."

The next steps for a plant-derived filovirus vaccine will involve using the EIC platform to design protection against the full range of these threadlike viruses. The method, with its straightforward purification protocol might also be used in the case of other pathogens including hepatitis C or dengue fever, where the extraction of glycoproteins has thus far been difficult.

Should efforts succeed in producing a post-exposure therapeutic that could be stockpiled by the U.S. military, the vaccine could also be made available to the Center for Disease Control for immediate use in the event of a remote outbreak.


'/>"/>
Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. Cells die so defensive organs can live
2. Rapid venom evolution in pit vipers may be defensive
3. Toward more cost-effective production of biofuels from plant lignocellulosic biomass
4. Leicester leads the way towards a sustainable lake in Africa
5. Advance toward a breath test to diagnose multiple sclerosis
6. Progress towards developing plants that accommodate climate change
7. Wildlife Conservation Society study uncovers a predictable sequence toward coral reef collapse
8. Award-winning research points toward Alzheimer’s vaccine
9. Another step toward resisting breast cancer
10. Toward new medications for chronic brain diseases
11. Toward a more efficient use of solar energy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Defensive measures: Toward a vaccine for Ebola  
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... travel across a colony to actively seek males which ... local dominant males. These findings, published in this ... widespread in nature than previously believed and that such ... from the University of Cambridge and the British Antarctic ...
... in increasingly large areas. , The summer of 2006 ... records began in 1895, according to the National Climatic Data ... 40 percent of the country. , When Constance Brown ... struck by a major difference: people in Indiana don't think ...
... million research program at Iowa State University dedicated ... grant is part of ConocoPhillips' plan to create ... viable solutions to diversify America's energy sources. ... grant in 2007 to support Iowa State researchers, ...
Cached Biology News:Female Antarctic seals give cold shoulder to local males 2How trees manage water in arid environments 2How trees manage water in arid environments 3How trees manage water in arid environments 4ConocoPhillips establishes $22.5M biofuels research program at Iowa State 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 3
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research ... on the current state of the global Propanol market with a focus on the ... Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , SOUTH SAN FRANCISCO, Calif., Sept. 15 ... 320 evaluable events (patient deaths) have occurred in its pivotal Phase 3 ... in accordance with a Special Protocol Assessment (SPA) with the U.S. Food ... lung cancer (SCLC). , , "The ...
... , BASKING RIDGE, N.J., Sept. 15 ... antithrombotic aptamers with active control agents, announced today that ... BioPharm America Conference 2009 in San Francisco, CA at 3:15 ... will include an overview of the Company,s pipeline with emphasis ...
... KVISTGAARD, Denmark, September 15 Bavarian,Nordic A/S (OMX: BAVA) announced ... undisclosed EU country for the delivery of a small order for,IMVAMUNE(R). ... of,the contract is undisclosed. , This marks ... for the delivery of IMVAMUNE(R), and it demonstrates that there,exists a ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 2Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 3Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 4Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 5Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009 2Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R) 2
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
Biology Products: